74
Participants
Start Date
January 19, 2020
Primary Completion Date
December 30, 2023
Study Completion Date
December 30, 2024
chidamide and toripalimab
"The eligible patients with advanced soft tissue sarcoma were treated with chidamide combined with toripalimb. Chidamide 30mg orally twice a week;~Toripalimab 240 mg (fixed dose) every three weeks.~Repeat every three weeks. Patients with disease control (CR + PR + SD) and tolerable adverse reactions continued to take medication until the researchers concluded that patients were not suitable to continue medication or the efficacy evaluation was disease progression (PD). No other antineoplastic treatment can be given during the treatment."
RECRUITING
Sun Yat-Sen Univerisity, Guangzhou
Sun Yat-sen University
OTHER